Novo Nordisk UK launches new type 2 diabetes treatment
Novo Nordisk UK has announced that Ozempic (semaglutide), a new once-weekly GLP-1 analogue injection for the treatment of Type 2 diabetes is now available in
Novo Nordisk UK has announced that Ozempic (semaglutide), a new once-weekly GLP-1 analogue injection for the treatment of Type 2 diabetes is now available in